Several reports have shown that Cdk4 hyperactivity is associated with the overexpression of cyclin D [37] and several cancers showing elevated levels of cyclin D1 expression including breast (60% of patients), CRC (40% of patients), and prostate cancers (20% of patients) [38]. Here, CDK4 is linked to prostate cancer.